Table 1.
Clinical and pathological characteristics of training set and external test set.
| Variables | Train Set (n=50581) | External Test Set (n=507) | ||
|---|---|---|---|---|
| NBM (%) N=45494 | BM (%) N=5087 | NBM (%) N=441 | BM (%) N=66 | |
| Race: | ||||
| Black | 4853 (10.7%) | 628 (12.3%) | 0 | 0 |
| White | 36818 (80.9%) | 3924 (77.1%) | 0 | 0 |
| Others | 3823 (8.40%) | 535 (10.5%) | 441 (100%) | 66 (100%) |
| Sex: | ||||
| Female | 22809 (50.1%) | 2189 (43.0%) | 206 (46.7%) | 28 (42.4%) |
| Male | 22685 (49.9%) | 2898 (57.0%) | 235 (53.3%) | 38 (57.6%) |
| Primary.Site: | ||||
| Main bronchus | 1097 (2.41%) | 200 (3.93%) | 13 (2.95%) | 5 (7.58%) |
| Upper lobe | 25860 (56.8%) | 2760 (54.3%) | 247 (56.0%) | 42 (63.6%) |
| Middle lobe | 2372 (5.21%) | 246 (4.84%) | 32 (7.26%) | 3 (4.55%) |
| Lower lobe | 14160 (31.1%) | 1434 (28.2%) | 137 (31.1%) | 14 (21.2%) |
| Others | 2005 (4.41%) | 447 (8.79%) | 12 (2.72%) | 2 (3.03%) |
| Grade: | ||||
| Grade I | 7090 (15.6%) | 302 (5.94%) | 113 (25.6%) | 5 (7.58%) |
| Grade II | 17875 (39.3%) | 1408 (27.7%) | 177 (40.1%) | 24 (36.4%) |
| Grade III | 19567 (43.0%) | 3217 (63.2%) | 148 (33.6%) | 35 (53.0%) |
| Grade IV | 962 (2.11%) | 160 (3.15%) | 3 (0.68%) | 2 (3.03%) |
| Laterality: | ||||
| Left | 18798 (41.3%) | 2129 (41.9%) | 164 (37.2%) | 29 (43.9%) |
| Right | 26393 (58.0%) | 2855 (56.1%) | 275 (62.4%) | 36 (54.5%) |
| Others | 303 (0.67%) | 103 (2.02%) | 2 (0.45%) | 1 (1.52%) |
| Histology: | ||||
| Adenocarcinoma | 24098 (53.0%) | 3113 (61.2%) | 312 (70.7%) | 42 (63.6%) |
| squamous cell carcinoma | 14106 (31.0%) | 1033 (20.3%) | 75 (17.0%) | 9 (13.6%) |
| Adenosquamous carcinoma | 696 (1.53%) | 65 (1.28%) | 9 (2.04%) | 1 (1.52%) |
| Large cell carcinoma | 668 (1.47%) | 89 (1.75%) | 2 (0.45%) | 1 (1.52%) |
| Others | 5926 (13.0%) | 787 (15.5%) | 43 (9.75%) | 13 (19.7%) |
| T stage: | ||||
| T1 | 15875 (34.9%) | 483 (9.49%) | 156 (35.4%) | 3 (4.55%) |
| T2 | 14885 (32.7%) | 1359 (26.7%) | 146 (33.1%) | 11 (16.7%) |
| T3 | 7984 (17.5%) | 1365 (26.8%) | 82 (18.6%) | 13 (19.7%) |
| T4 | 6750 (14.8%) | 1880 (37.0%) | 57 (12.9%) | 39 (59.1%) |
| N stage: | ||||
| N0 | 27907 (61.3%) | 1027 (20.2%) | 269 (61.0%) | 13 (19.7%) |
| N1 | 4431 (9.74%) | 482 (9.48%) | 36 (8.16%) | 5 (7.58%) |
| N2 | 10121 (22.2%) | 2389 (47.0%) | 106 (24.0%) | 35 (53.0%) |
| N3 | 3035 (6.67%) | 1189 (23.4%) | 30 (6.80%) | 13 (19.7%) |
| Chemotherapy: | ||||
| NO | 29077 (63.9%) | 2110 (41.5%) | 274 (62.1%) | 23 (34.8%) |
| YES | 16417 (36.1%) | 2977 (58.5%) | 167 (37.9%) | 43 (65.2%) |
| Marital | ||||
| Unmarride | 12987 (28.5%) | 1504 (29.6%) | – | – |
| Married | 32507 (71.5%) | 3583 (70.4%) | – | – |
| Age: | ||||
| <=60 | 8944 (19.7%) | 1260 (24.8%) | 79 (17.9%) | 20 (30.3%) |
| >60 | 36550 (80.3%) | 3827 (75.2%) | 362 (82.1%) | 46 (69.7%) |
BM, bone metastasis; NBM, no bone metastasis.